The Influences of Blood Flow Restriction on Leg Press

NCT ID: NCT07052227

Last Updated: 2025-07-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2025-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the use of different blood flow restriction cuffs during leg press exercise on arterial stiffness, muscle morphology, performance, and participant perception.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to investigate the use of Delfi vs. Fitcuffs blood flow restriction (BFR) cuff exercise on indices of arterial stiffness, muscle morphology, performance, and participant perception. Thirty adults aged 18-40 years old will undergo three treatment sessions (control (no BFR), Delfi BFR, and Fitcuffs BFR) in a randomized order separated by one week. A familiarization session will also occur one week before starting the treatment period. Each subject will undergo a series of tests including anthropometry, applanation tonometry, ultrasonography of the vastus lateralis, blood pressure acquisition, body composition, and maximal strength assessments (1RM). The exercise trial will consist of sets of leg press exercises performed to failure with a 2-second concentric and 2-second eccentric cadence at 20% of their 1RM using 60% of the supine limb occlusion pressure (LOP) with 1-minute rest intervals. Assessments will be performed immediately before and after the exercise bout during each treatment session. Two-way ANOVAs will be used to examine the main effects of treatment and treatment-order interaction on pulse wave velocity, muscle cross-sectional area, and perceptual response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delfi Cuff Fitcuff Placebo - Control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Delfi

Group Type EXPERIMENTAL

Delfi blood flow restriction cuff

Intervention Type DEVICE

Leg press exercise with Delfi blood flow restriction cuff

Fitcuff

Group Type EXPERIMENTAL

Fitcuffs

Intervention Type DEVICE

Leg press exercise with Fitcuff blood flow restriction cuff

Control

Group Type PLACEBO_COMPARATOR

Control

Intervention Type OTHER

Leg press exercise with no blood flow restriction cuff

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Delfi blood flow restriction cuff

Leg press exercise with Delfi blood flow restriction cuff

Intervention Type DEVICE

Fitcuffs

Leg press exercise with Fitcuff blood flow restriction cuff

Intervention Type DEVICE

Control

Leg press exercise with no blood flow restriction cuff

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Physically active (\> 1,000 MET/min/wk) for at least six months.
2. Weight stable for previous 6 months (+/-2.5 kg)

Exclusion Criteria

1. Stage 2 hypertension (SBP \>/= 140 and/or DBP \>/= 90 mmHg)
2. BMI\>40 kg/m2
3. Diabetes
4. Familial hypercholesterolemia
5. Past or current history of CHD, stroke or major CVD events. Respiratory diseases (not including asthma), endocrine or metabolic, neurological, or hematological disorders that would compromise the study or the health of the subject.
6. Participants must not be pregnant, plan to become pregnant during the study, or be nursing
7. Active renal or liver disease
8. All medications and supplements that influence dependent variables\*
9. Recent surgery \< 2 months
10. Alcohol abuse
11. Sleep apnea
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Salisbury University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Timothy Werner

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Salisbury University

Salisbury, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tim Werner, PhD

Role: CONTACT

410-548-3526

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tim Werner

Role: primary

740-434-7720

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

#492

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.